Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab and BioNTech SE have launched a first-in-human study titled ‘A First-in-Human, Open-label, Dose-finding Trial to Evaluate the Safety and Antitumor Activity of GEN1056 in Subjects With Advanced Solid Tumors.’ The study aims to assess the safety and antitumor activity of GEN1056, a potential treatment for patients with advanced solid tumors who have no standard care options. This study is significant as it seeks to establish a recommended dose and frequency for future trials.
The intervention being tested is GEN1056, a biological treatment administered via intravenous infusion. It is intended to evaluate safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors.
The study is designed as an open-label, sequential intervention model with no masking, focusing on treatment. It consists of two parts: dose escalation to explore safety and dose schedule optimization based on initial findings.
Key dates for the study include an actual start date of October 24, 2022, with the latest update submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
The market implications of this study update could be significant for Genmab and BioNTech SE, potentially influencing their stock performance and investor sentiment. The progress in developing GEN1056 may also impact the competitive landscape in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.